MX2018013567A - L-carnitina multiparticulada y composiciones nootropicas y metodos relacionados. - Google Patents

L-carnitina multiparticulada y composiciones nootropicas y metodos relacionados.

Info

Publication number
MX2018013567A
MX2018013567A MX2018013567A MX2018013567A MX2018013567A MX 2018013567 A MX2018013567 A MX 2018013567A MX 2018013567 A MX2018013567 A MX 2018013567A MX 2018013567 A MX2018013567 A MX 2018013567A MX 2018013567 A MX2018013567 A MX 2018013567A
Authority
MX
Mexico
Prior art keywords
carnitine
multiparticulate
release
related methods
active ingredients
Prior art date
Application number
MX2018013567A
Other languages
English (en)
Inventor
M Shah Syed
Hassan Daniel
Hassan Fred
Diorio Christopher
Hassan Noreen
Original Assignee
Physicians Seal Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Physicians Seal Llc filed Critical Physicians Seal Llc
Publication of MX2018013567A publication Critical patent/MX2018013567A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición incluye una forma de dosificación farmacéutica terapéuticamente eficaz que incluye una pluralidad de partículas individuales. Las partículas individuales tienen respectivamente: un núcleo que incluye una combinación de ingredientes activos de una L-carnitina y una sustancia nootrópica y un polímero que controla la liberación sobre el núcleo que previene sustancialmente la liberación de los ingredientes activos en el ácido del estómago y permite la liberación de los ingredientes activos en un ambiente de pH intestinal. La composición puede usarse para tratar afecciones asociadas con una reducción de la cantidad de L-carnitina en el cuerpo y/o deterioro cognitivo.
MX2018013567A 2016-05-06 2017-05-04 L-carnitina multiparticulada y composiciones nootropicas y metodos relacionados. MX2018013567A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662332683P 2016-05-06 2016-05-06
PCT/US2017/031022 WO2017192828A1 (en) 2016-05-06 2017-05-04 Multiparticulate l-carnitine and nootropic compositions and related methods

Publications (1)

Publication Number Publication Date
MX2018013567A true MX2018013567A (es) 2019-01-31

Family

ID=60203745

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018013567A MX2018013567A (es) 2016-05-06 2017-05-04 L-carnitina multiparticulada y composiciones nootropicas y metodos relacionados.
MX2021012580A MX2021012580A (es) 2016-05-06 2018-11-06 L-carnitina multiparticulada y composiciones nootropicas y metodos relacionados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021012580A MX2021012580A (es) 2016-05-06 2018-11-06 L-carnitina multiparticulada y composiciones nootropicas y metodos relacionados.

Country Status (3)

Country Link
CA (1) CA3023687A1 (es)
MX (2) MX2018013567A (es)
WO (1) WO2017192828A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008134143A (ru) * 2008-08-21 2010-02-27 Тимофей Георгиевич Кожока (RU) Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения
US8828426B2 (en) * 2011-06-07 2014-09-09 Zx Pharma, Llc Multiparticulate L-carnitine compositions and related methods

Also Published As

Publication number Publication date
CA3023687A1 (en) 2017-11-09
MX2021012580A (es) 2021-11-12
WO2017192828A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
MX2021016109A (es) Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion.
MX2021013139A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
SG11201912110YA (en) Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient
EP4324454A3 (en) Cross-linking agents and associated methods
EP4218823A3 (en) Novel polymeric hgh prodrugs
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
EP3336100A4 (en) PEPTIDE WITH EFFECT FOR PREVENTING OR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM THEREFOR AS AN ACTIVE SUBSTANCE
IL270159B (en) Preparations containing nanometer particles for the administration of drugs for the treatment of eye diseases
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
WO2012106058A3 (en) Animal treatments
EP3934639A4 (en) FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE DISORDERS, BEHAVIORAL DISORDERS AND CHRONIC PAIN
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
MX2021012580A (es) L-carnitina multiparticulada y composiciones nootropicas y metodos relacionados.
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
ZA201905309B (en) Pharmaceutical active ingredient and use thereof, in particular for the prevention and treatment of metabolic disorders in humans and animals
EP3818981C0 (en) SYNERGISTIC PHARMACEUTICAL COMPOSITION OF THE ACTIVE ENANTIOMER (S)-KETOROLAC AND GABAPENTIN FOR THE TREATMENT OF NEUROPATHIC PAIN
EP3777849A4 (en) PHARMACEUTICAL COMPOSITION, COMPRISING POLMACOXIB AND PREGABALIN, FOR THE TREATMENT OF PAIN
MX2018011539A (es) Tratamiento de dolencias y enfermedades cutaneas asociadas a biopeliculas microbianas.
MX2018011293A (es) Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma.
EP3338792A4 (en) CORNEAL LESION PREVENTION / TREATMENT COMPOSITION COMPRISING ACTIVE PRINCIPLES OF THYMOSINE BETA 4 AND CITRIC ACID
WO2017067664A9 (en) Oxa-diazaspiro compounds having activity against pain
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
WO2016091805A3 (de) Naloxon-monopräparat und mehrschichttablette